Sep 11th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

GSK plc (LSE/NYSE: GSK) released encouraging top-line outcomes from MATINEE in adult patients suffering from chronic obstructive pulmonary disease (COPD).

Competing in the $40 Billion Alopecia Areata Market: Hengrui's JAK1 Inhibitor Ivarmacitinib Receives Approval for New Indication Application.

Ventyx Biosciences announced that the initial patient has been administered a dose in a Phase 2a study of VTX3232 for individuals with early-stage Parkinson’s disease.

Cytonics Completes Phase 1 Enrollment for Study on CYT-108, a New Protease Inhibitor, in Knee Osteoarthritis Patients.

Sep 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Huonslab Reveals Favorable In Vivo PK Study Outcomes for Trastuzumab/HyDIFFUZETM vs. Commercial rHuPH20 and Trastuzumab Co-formulation.

NextPoint Therapeutics Reveals NPX372, a Novel Drug Targeting B7-H7 in Solid Tumors, as New T Cell Engager.

Medigene Gets U.S. FDA Approval for IND of MDG1015, a Novel Third Gen T Cell Therapy Targeting Various Solid Tumors.

Boehringer Ingelheim reveals intention to progress a promising new therapy for Geographic Atrophy, inspired by favorable Phase I outcomes.

B7-H3 (also known as CD276) is a type I transmembrane glycoprotein and a member of the B7 family.

In a pioneering fixed dose study, weekly insulin efsitora alfa achieves A1C reduction comparable to that of daily insulin.